Keith Steele is a prominent inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic antibodies. With a total of 3 patents, Steele has established himself as a key figure in the medical research community.

Latest Patents

Among his latest patents, Steele has developed Anti-B7-H1 antibodies for treating tumors. These patents detail methods of treating B7-H1-expressing tumors by administering an effective amount of MEDI4736 or an antigen-binding fragment thereof. This groundbreaking work aims to improve treatment options for patients suffering from various forms of cancer.

Career Highlights

Steele is currently associated with MedImmune Limited, where he continues to push the boundaries of cancer research. His work has garnered attention for its potential to change the landscape of tumor treatment. His dedication to innovation in this field is evident through his ongoing research and development efforts.

Collaborations

Steele has collaborated with notable colleagues, including Rajesh Narwal and David Fairman. These partnerships have further enhanced his research capabilities and contributed to the advancement of cancer therapies.

Conclusion

In summary, Keith Steele is a dedicated inventor whose work in developing Anti-B7-H1 antibodies represents a significant advancement in cancer treatment. His contributions to the field are invaluable, and his ongoing research promises to lead to new therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.